Drug intelligence / Profile preview

STT-002

Development stage: Preclinical
Lead developer: STCube
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

STT-002 is a preclinical-stage monoclonal antibody developed by STCube & Company. It functions as an immune checkpoint inhibitor by specifically targeting the Programmed Cell Death Protein 1 (PD-1) receptor. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), STT-002 aims to restore the anti-tumor activity of T cells, which is often suppressed in the tumor microenvironment. The drug is being investigated for the treatment of various solid tumors, including melanoma, lung cancer, and head and neck cancer.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on STT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STT-002.

Explore the full profile